| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
COX-1/cyclooxygenase-1 (IC50 = 7.5 μM)
|
|---|---|
| ln Vitro |
(-)-Epicatechin gallate has an IC50 of 7.5 μM and >95% inhibitory action against cyclooxygenase-1 (COX-1) at 70 μg/mL[1].
|
| ln Vivo |
(-)-Epicatechin gallate, an active ingredient in Onpi-to, a herbal remedy made of five herbal medicines (dry ginger, ginseng, rhubarb, licorice, and tubers), is one of the components of rhubarb. A three-compartment model was able to fit the plasma concentration versus time curve in rats that had received an intravenous dose of (-)-epicatechin gallate (1.0 mg/kg). assessment of plasma epicatechin gallate's pharmacokinetic characteristics (ECG). The ECG's t1/2α, t1/2β, and t1/2γ are 0.038, 0.291, and 4.033 hours, respectively. The electrocardiogram's CLtot is 4.19 L/h • kg. 12.39 L/kg is the Vdss[2].
|
| Enzyme Assay |
Moderate consumption of wine is associated with a reduced risk of cancer. Grape plant cell cultures were used to purify 12 phenols: the stilbenoids trans-astringin, trans-piceid (2), trans-resveratroloside, trans-resveratrol, trans-piceatannol, cis-resveratroloside, cis-piceid, and cis-resveratrol; the flavans (+)-catechin, (-)-epicatechin, and epicatechin 3-O-gallate; and the flavan dimer procyanidin B2 3'-O-gallate. These compounds were evaluated for potential to inhibit cyclooxygenases and preneoplastic lesion formation in carcinogen-treated mouse mammary glands in organ culture. At 10 micrograms/ml, trans-astringin and trans-piceatannol inhibited development of 7,12-dimethylbenz[a]anthracene-induced preneoplastic lesions in mouse mammary glands with 68.8% and 76.9% inhibition, respectively, compared with untreated glands. The latter compound was the most potent of the 12 compounds tested in this assay, with the exception of trans-resveratrol (87.5% inhibition). In the cyclooxygenase (COX)-1 assay, trans isomers of the stilbenoids appear to be more active than cis isomers: trans-resveratrol [50% inhibitory concentration (IC50) = 14.9 microM, 96%] vs. cis-resveratrol (IC50 = 55.4 microM). In the COX-2 assay, among the compounds tested, only trans- and cis-resveratrol exhibited significant inhibitory activity (IC50 = 32.2 and 50.2 microM, respectively). This is the first report showing the potential cancer-chemopreventive activity of trans-astringin, a plant stilbenoid recently found in wine. trans-Astringin and its aglycone trans-piceatannol were active in the mouse mammary gland organ culture assay but did not exhibit activity in COX-1 and COX-2 assays. trans-Resveratrol was active in all three of the bioassays used in this investigation. These findings suggest that trans-astringin and trans-piceatannol may function as potential cancer-chemopreventive agents by a mechanism different from that of trans-resveratrol[1].
|
| ADME/Pharmacokinetics |
(-)-Epicatechin-3-O-gallate (ECG) is a component of rhubarb and an active ingredient in a traditional Chinese medicine compound preparation (rhubarb, licorice, ginseng, ginger, and aconite), which has been used to treat patients with chronic renal failure. This study investigated the pharmacokinetics of ECG in male rats using high-performance liquid chromatography-electrochemical detection (HPLC-ECD). 1. After oral administration of ECG, plasma ECG concentration peaks appeared at 0.065, 0.063, and 0.085 hours, corresponding to doses of 12.5, 25.0, and 50.0 mg/kg, with average concentrations of 49.62, 212.89, and 464.04 ng/ml, respectively. Subsequently, plasma ECG concentrations decreased exponentially. 2. The pharmacokinetic characteristics of ECG were nonlinear, with both Cmax and AUC0-inf values showing nonlinear changes. 2. At doses of 12.5, 25.0, and 50.0 mg/kg, the absolute bioavailability (F) was 1.02%, 1.47%, and 3.30%, respectively. 3. After intravenous ECG administration, plasma ECG concentration decreased with increasing γ elimination half-life (t1/2γ), with a half-life of 4.03 hours. 4. After oral ECG administration, urinary ECG concentration was below the limit of quantification. In addition, within 30 hours after administration, the cumulative excretion of metabolites δ-(3,4-dihydroxyphenyl)-γ-valerolactone and δ-(3-methoxy-4-hydroxyphenyl)-γ-valerolactone was 2.45% and 0.23% of the administered dose, respectively. [2]
|
| References | |
| Additional Infomation |
(-)-Epicatechin-3-O-gallate is a gallate ester formed by the condensation of the carboxyl group of gallic acid and the (3R)-hydroxyl group of epicatechin. It is a natural product discovered in Parapiptadenia rigida. It is a metabolite and also an inhibitor of EC 3.2.1.1 (α-amylase) and EC 3.2.1.20 (α-glucosidase). It is a catechin, gallate, and polyphenol compound. Its function is related to (-)-epicatechin and gallic acid. (-)-Epicatechin gallate has been found in tea (Camellia sinensis), peony (Paeonia obovata), and other organisms with relevant data.
|
| Molecular Formula |
C22H18O10
|
|---|---|
| Molecular Weight |
442.37 Exact Mass
|
| Exact Mass |
442.089
|
| Elemental Analysis |
C, 59.73; H, 4.10; O, 36.17
|
| CAS # |
1257-08-5
|
| Related CAS # |
(-)-Epicatechin;490-46-0
|
| PubChem CID |
107905
|
| Appearance |
White to off-white solid powder
|
| Density |
1.8±0.1 g/cm3
|
| Boiling Point |
861.7±65.0 °C at 760 mmHg
|
| Melting Point |
257-258ºC
|
| Flash Point |
305.0±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.825
|
| LogP |
2.67
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
32
|
| Complexity |
649
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C=C3)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O
|
| InChi Key |
LSHVYAFMTMFKBA-TZIWHRDSSA-N
|
| InChi Code |
InChI=1S/C22H18O10/c23-11-6-14(25)12-8-19(32-22(30)10-4-16(27)20(29)17(28)5-10)21(31-18(12)7-11)9-1-2-13(24)15(26)3-9/h1-7,19,21,23-29H,8H2/t19-,21-/m1/s1
|
| Chemical Name |
[(2R,3R)-2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
|
| Synonyms |
Epicatechin-3-O-gallate; (-)-Epicatechin gallate; 1257-08-5; Epicatechin gallate; (-)-epicatechingallate; (-)-Epicatechin-3-O-gallate; L-Epicatechin gallate; epicatechin monogallate; (-)-Epicatechin-3-gallate; Epicatechin 3-gallate; ECG
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 30 mg/mL (~67.82 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.17 mg/mL (4.91 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
